The AAFPRS reports an increase in women citing menopause during aesthetic consultations. Learn the clinical evidence linking midlife hormones to facial aging.
The American Academy of Facial Plastic and Reconstructive Surgery reported in its 2025 annual member survey that 45 percent of surveyed surgeons saw more female patients citing menopause or perimenopause as a treatment reason. This marks a notable increase from the 28 percent reported in 2024.
Historically, aesthetic medicine treated visible facial aging as a uniform process driven primarily by chronological age and environmental factors. Clinicians focused on cumulative sun damage and basic gravity, treating skin laxity as an isolated mechanical issue. The standard of care rarely incorporated a patient's systemic hormonal status into the cosmetic consultation. Aesthetic concerns were separated entirely from the physiological transitions occurring elsewhere in a woman's body.
Patients seeking treatment were often offered generalized solutions that did not account for their specific biological context. A woman might discuss her skin texture with a dermatologist, but she would manage her internal health with a primary care physician. This clinical division meant that menopause was practically absent from the aesthetic consultation room. Standard aging protocols offered uniform procedures, treating all patients of a certain age with similar interventions.
The medical consensus previously offered little nuance regarding how declining estrogen altered the structural foundations of the face. Clinicians rarely acknowledged the sudden physiological shifts that occur during perimenopause and early postmenopause. Consequently, women often felt pressure to chase superficial fixes without understanding the underlying metabolic and hormonal mechanisms. This old paradigm ignored the reality that midlife hormonal transitions significantly influence skin behavior.
This disconnect often left women feeling responsible for changes they could not control with over-the-counter products. When patients brought concerns about rapid skin changes to their doctors, the lack of a systemic explanation frequently caused frustration. The historical separation of dermatological care and gynecological care meant that few specialists looked at the complete midlife health perspective. As a direct consequence, many women spent years navigating trial-and-error cosmetic approaches that yielded minimal results.
Today, the aesthetic industry is documenting a distinct change in how patients communicate their needs. The AAFPRS represents more than 2,200 facial plastic and reconstructive surgeons worldwide. Its recent announcement describes a clear shift in the consultation room, where more women are explicitly connecting midlife hormonal transitions with visible facial changes. Patients are increasingly asking clinicians what facial changes are expected during menopause.
The biological context provides a clear rationale for why patients notice accelerated changes during midlife. The American Academy of Dermatology states that declining estrogen during menopause is associated with thinner skin, easier bruising and rapid collagen loss. The organization reports that women lose approximately 30 percent of their skin collagen during the first five years of menopause. Following this initial steep decline, collagen loss continues at a more gradual pace.
A recent review further quantifies these postmenopausal structural changes. It describes an average annual decline of approximately 2.1 percent in collagen and 1.5 percent in skin elasticity. The review notes that lower hormone levels may also reduce dermal water retention and surface oil production. These specific biological mechanisms help explain why some women perceive faster changes in facial laxity or texture during perimenopause.
While the biological connection is clear, the evidence regarding treatment efficacy remains nuanced. A 2026 systematic review and meta-analysis examined the effects of menopausal hormone therapy on skin structure. The study reported statistically significant improvements in skin elasticity, thickness and collagen content among women using the therapy. It found standardized mean differences of 0.28 for elasticity, 1.27 for thickness and 2.01 for collagen content.
The same analysis found that menopausal hormone therapy did not produce a statistically significant improvement in skin dryness. The reported effect for dryness was a standardized mean difference of 0.15, with a 95 percent confidence interval crossing zero. Furthermore, the available medical literature does not justify starting systemic hormone therapy solely to pursue a younger-looking face. Decisions about hormone therapy should prioritize an individual's overall indications and health risks over aesthetic objectives alone.
A review of estrogen and skin function supports a measured perspective on outcomes. The review reports more consistent findings for collagen content, dermal thickness and elasticity. Conversely, findings remain inconsistent regarding estrogen's impact on wrinkles, sebaceous secretions and blood flow. This mixed evidence clarifies why biological plausibility should never be confused with guaranteed treatment efficacy.
As consultations evolve, clinical organizations are updating their guidance for managing menopausal skin. The following points detail specific discoveries and updated protocols based on recent evidence:
The timing and degree of facial changes vary substantially between individuals. The AAFPRS cautions that no two patients experience menopause in exactly the same way. Variables such as chronological age, genetics, sun exposure and smoking heavily influence an individual's appearance. Therefore, menopause should never be treated as a single standardized facial-aging experience.
Aesthetic concerns can carry an emotional dimension, but cosmetic treatment is not a requirement for a successful midlife transition. Patients should use menopause as useful context in a consultation, rather than treating it as a diagnosis that dictates a specific procedure. A woman might explain when changes began and whether they fluctuate with perimenopause. She can specify which concerns matter most, recognizing that several factors may be involved.
Procedures carry medical, financial and psychological considerations that require individualized discussion. Patients must understand the expected benefits, alternatives, risks and the possibility that results may be limited. Wanting a refreshed appearance is valid, but evaluating whether sleep disruption or body-image pressure influences the decision is equally valuable. Accessing resources on physical and emotional shifts can help clarify these personal motivations.
It is vital to ask clinicians to separate distinct aesthetic goals during consultations. Improving skin hydration requires completely different interventions than restoring facial volume or tightening lax skin. The appropriate intervention depends entirely on the specific concern and the person's unique medical history. Patients should be cautious of any treatment marketed as a universal menopause solution, as the evidence does not support one single protocol.
The reported 45 percent figure is a valuable observation, but it is not a prevalence estimate for all women. It represents the proportion of surveyed facial plastic surgeons who observed more female patients citing menopause as a treatment reason. The survey measures what surgeons report hearing from patients during clinical visits. It does not measure the total number of women seeking treatment nationally.
The comparison between 45 percent and 28 percent indicates a year-over-year increase in surgeons' reported observations. However, the available release does not provide the survey's sample size, response rate or question wording. It also lacks a geographic breakdown and statistical significance testing. Because this statistic originates from a professional association, it represents an association survey finding rather than an independently verified market measure.
The AAFPRS announcement intentionally places facial changes within a broader public conversation about midlife hormonal transitions. Notably, the announcement arrives ahead of October’s Menopause Awareness Month. The organization does not claim that aesthetic procedures treat menopause itself or reverse systemic hormonal changes. Cosmetic treatments are not presented as medical interventions that improve a woman's general systemic wellbeing.
Distinguishing between professional observations and clinical treatment guidelines is vital for patient safety. An increase in patient inquiries does not automatically mean that more women require surgical intervention. It simply indicates that the consultation environment is becoming more transparent regarding midlife changes. Patients should use these conversations to gather information, remaining aware that biological plausibility does not equal cosmetic necessity.
This development represents a communication trend as much as a clinical treatment trend. Women appear more willing to explicitly name menopause during their aesthetic consultations. Concurrently, clinicians are receiving encouragement to listen closely to both the physical changes and the patient's personal goals. The primary clinical task is to understand a patient's concerns in the context of her overall health.
Clinicians must evaluate a woman's specific position in the menopause transition rather than assuming one treatment fits everyone. Reading research-led articles on skin health provides additional context for these clinical conversations.
Going forward, clinical practice will increasingly view facial aging as part of a broader physiological transition rather than an isolated cosmetic flaw to erase.
While consulting a board-certified facial plastic surgeon provides clarity on aesthetic procedures, interpreting the wider physiological landscape of midlife requires a broader perspective. Refemina clarifies conflicting information about perimenopause, menopause and postmenopause, providing clear adult guidance without symptom panic or anti-aging pressure.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources